{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:53:58Z","timestamp":1791158038135,"version":"4.1.0"},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/hjh.0b013e3283599b6a","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T18:18:06Z","timestamp":1348597086000},"page":"3-15","source":"Crossref","is-referenced-by-count":96,"title":["Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension"],"prefix":"10.1097","volume":"31","author":[{"given":"GianLuca","family":"Colussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Catena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210219","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure.","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"key":"R2-2-20210219","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1966.03110240051022","article-title":"Treatment of hypertension with spironolactone. Double-blind study.","volume":"198","author":"Wolf","year":"1966","journal-title":"JAMA"},{"key":"R3-2-20210219","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jps.2600660841","article-title":"Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.","volume":"66","author":"Phelps","year":"1977","journal-title":"J Pharm Sci"},{"key":"R4-2-20210219","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists.","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R5-2-20210219","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R6-2-20210219","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"R7-2-20210219","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R8-2-20210219","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-2-20210219","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-2-20210219","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-2-20210219","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","article-title":"Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism.","volume":"89","author":"Sywak","year":"2002","journal-title":"Br J Surg"},{"key":"R12-2-20210219","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-2-20210219","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","article-title":"Medical management of aldosterone-producing adenomas.","volume":"131","author":"Ghose","year":"1999","journal-title":"Ann Intern Med"},{"key":"R14-2-20210219","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"R15-2-20210219","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R16-2-20210219","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R17-2-20210219","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R18-2-20210219","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conns Registry.","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-2-20210219","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renaldamage in primary aldosteronism: results of the PAPY Study.","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"R20-2-20210219","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism.","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-2-20210219","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-2-20210219","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.","volume":"25","author":"Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"R23-2-20210219","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","article-title":"Primary aldosteronism: cardiovascular, renal and metabolic implications.","volume":"19","author":"Rossi","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"R24-2-20210219","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment.","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"R25-2-20210219","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism.","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"R26-2-20210219","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2215\/CJN.00050107","article-title":"Relationships of plasma renin levels with renal function in patients with primary aldosteronism.","volume":"2","author":"Catena","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-2-20210219","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","article-title":"Intrarenal hemodynamics in primary aldosteronism before and after treatment.","volume":"94","author":"Sechi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-2-20210219","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/ajh\/6.11.907","article-title":"Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma.","volume":"6","author":"Denolle","year":"1993","journal-title":"Am J Hypertens"},{"key":"R29-2-20210219","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"R30-2-20210219","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism.","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"R31-2-20210219","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"R32-2-20210219","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.108.114140","article-title":"Inappropriate leftventricular mass in patients with primary aldosteronism.","volume":"52","author":"Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"R34-2-20210219","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0b013e328126855b","article-title":"Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment.","volume":"25","author":"Novello","year":"2007","journal-title":"J Hypertens"},{"key":"R35-2-20210219","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study.","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-2-20210219","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension.","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"R37-2-20210219","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.","volume":"13","author":"Epstein","year":"2011","journal-title":"J Clin Hypertens"},{"key":"R39-2-20210219","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonistimprovesdiastolicfunction in essentialhypertension.","volume":"40","author":"Grandi","year":"2002","journal-title":"Hypertension"},{"key":"R40-2-20210219","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1291\/hypres.25.837","article-title":"Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension.","volume":"25","author":"Sato","year":"2002","journal-title":"Hypertens Res"},{"key":"R41-2-20210219","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.","volume":"70","author":"Taniguchi","year":"2006","journal-title":"Circ J"},{"key":"R42-2-20210219","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"R43-2-20210219","first-page":"261","article-title":"Effects of spironolactone-altizide on left ventricular hypertrophy.","volume":"53","author":"Degre","year":"1998","journal-title":"Acta Cardiol"},{"key":"R44-2-20210219","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"R45-2-20210219","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenoneenalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"R46-2-20210219","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/clc.4960281008","article-title":"Spironolactone improves diastolic function in the elderly.","volume":"28","author":"Roongsritong","year":"2005","journal-title":"Clin Cardiol"},{"key":"R47-2-20210219","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"R48-2-20210219","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"R49-2-20210219","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"R50-2-20210219","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R51-2-20210219","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.","volume":"6","author":"Saruta","year":"2004","journal-title":"J Clin Hypertens"},{"key":"R52-2-20210219","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R53-2-20210219","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension.","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"R54-2-20210219","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"R55-2-20210219","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"R56-2-20210219","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R57-2-20210219","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"R58-2-20210219","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","article-title":"Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"key":"R59-2-20210219","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"key":"R60-2-20210219","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension.","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"R61-2-20210219","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension.","volume":"44","author":"Marrs","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R62-2-20210219","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension"},{"key":"R63-2-20210219","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension.","volume":"4","author":"Engbaek","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"R64-2-20210219","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension.","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R65-2-20210219","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension.","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R66-2-20210219","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension.","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"R67-2-20210219","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"R68-2-20210219","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study.","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"R69-2-20210219","first-page":"520","article-title":"What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated Curr Cardiol R","volume":"13","author":"Sica","year":"2011","journal-title":"ep"},{"key":"R70-2-20210219","first-page":"2974","article-title":"How does proteinuria cause progressive renal damage J Am Soc N","volume":"17","author":"Abbate","year":"2006","journal-title":"ephrol"},{"key":"R71-2-20210219","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"R72-2-20210219","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ki.1978.114","article-title":"Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure.","volume":"14","author":"Berl","year":"1978","journal-title":"Kidney Int"},{"key":"R73-2-20210219","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease.","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"R74-2-20210219","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria.","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"R75-2-20210219","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy.","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"R76-2-20210219","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R77-2-20210219","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R78-2-20210219","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"R79-2-20210219","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"R80-2-20210219","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R81-2-20210219","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on nondiabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"R82-2-20210219","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R83-2-20210219","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system.","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R84-2-20210219","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/bmj.38883.479549.2F","article-title":"Spironolactone and risk of upper gastrointestinal events: population based case-control study.","volume":"333","author":"Verhamme","year":"2006","journal-title":"BMJ"},{"key":"R85-2-20210219","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2008.03205.x","article-title":"Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study.","volume":"66","author":"Gulmez","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R86-2-20210219","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/pds.1583","article-title":"Spironolactone and gastrointestinal bleeding: a population based study.","volume":"17","author":"Russo","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R87-2-20210219","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension.","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"R88-2-20210219","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"R89-2-20210219","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R90-2-20210219","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone use and renal toxicity: population based longitudinal analysis.","volume":"340","author":"Wei","year":"2010","journal-title":"BMJ"},{"key":"R91-2-20210219","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"R92-2-20210219","doi-asserted-by":"crossref","first-page":"d5228","DOI":"10.1136\/bmj.d5228","article-title":"Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study.","volume":"343","author":"Antoniou","year":"2011","journal-title":"BMJ"},{"key":"R93-2-20210219","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","article-title":"Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.","volume":"225","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"key":"R94-2-20210219","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"R95-2-20210219","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"R96-2-20210219","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","article-title":"The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.","volume":"635","author":"Kosaka","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"R97-2-20210219","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R98-2-20210219","first-page":"319","article-title":"Aldosterone synthase inhibitors: pharmacological and clinical aspects.","volume":"10","author":"Jansen","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R99-2-20210219","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1210\/mend-5-10-1513","article-title":"The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex.","volume":"5","author":"Curnow","year":"1991","journal-title":"Mol Endocrinol"},{"key":"R100-2-20210219","first-page":"4156","article-title":"Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene.","volume":"83","author":"Portrat-Doyen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R101-2-20210219","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2003.08.034","article-title":"Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension.","volume":"43","author":"Stella","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R102-2-20210219","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.hjh.0000254372.88488.a9","article-title":"Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis.","volume":"25","author":"Sookoian","year":"2007","journal-title":"J Hypertens"},{"key":"R103-2-20210219","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats.","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"R104-2-20210219","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"R105-2-20210219","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"R106-2-20210219","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"R107-2-20210219","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/HJH.0b013e32833c2197","article-title":"FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.","volume":"28","author":"Gamliel-Lazarovich","year":"2010","journal-title":"J Hypertens"},{"key":"R108-2-20210219","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"R109-2-20210219","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"R110-2-20210219","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0b013e3283599b6a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:39:42Z","timestamp":1621885182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201301000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283599b6a","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}